JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online October 16, 2008, 10.2967/jnumed.108.050591
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.050591v1
49/11/1776    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosário, P. W.
Right arrow Articles by Purisch, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosário, P. W.
Right arrow Articles by Purisch, S.
Journal of Nuclear Medicine Vol. 49 No. 11 1776-1782
© 2008 by Society of Nuclear Medicine
doi: 10.2967/jnumed.108.050591

Clinical Investigation

Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity

Pedro Weslley Rosário, Michelle Aparecida Ribeiro Borges and Saulo Purisch

Department of Thyroid, Endocrinology Service, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil

Correspondence: For correspondence or reprints contact: Pedro Weslley Rosário, Centro de Estudos e Pesquisa da Clinica de Endocrinologia e Metabologia (CEPCEM), Av Francisco Sales, 1111 Santa Efigênia 5 D, CEP 30150-221, Belo Horizonte, MG, Brasil. E-mail: pedrorosario{at}globo.com


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 CONCLUSION
 References
 
Preparation with recombinant human thyroid-stimulating hormone (rhTSH) for thyroid remnant ablation results in lower extrathyroidal radiation than does hypothyroidism. The objective of this prospective study was to compare the damage caused by 131I (3.7 GBq) when these 2 preparations are used. Methods: Ninety-four consecutive patients who underwent total thyroidectomy and remnant ablation with 3.7 GBq of 131I were studied. Thirty patients (group A) received rhTSH, and 64 (group B) were prepared by levothyroxine withdrawal. Damage to salivary glands, ovaries, and testes; hematologic damage; and oxidative injury were evaluated by measurement of serum amylase, follicle-stimulating hormone (FSH), complete blood count, and plasma 8-epi-PGF2{alpha} before and after radioiodine. The 2 groups were similar in sex, age, and the results of baseline assessment. Results: The rate of successful ablation (stimulated thyroglobulin level < 1 ng/mL and negative findings on neck ultrasonography) was 90% in group A and 80% in group B. Considering only patients with a preablation thyroglobulin level greater than 1 ng/mL, these rates were 80% and 70.6%, respectively. Only 1 patient (3.3%) reported transient headaches with rhTSH. Elevated FSH levels after therapy were observed in 4 of 9 (44%) men in group A versus 16 of 18 (89%) in group B (P < 0.03), with a mean increase of 105% versus 236% (P < 0.001), respectively. In women, elevated FSH was observed in 1 of 13 (7.7%) patients in group A versus 6 of 30 (20%) in group B (P = 0.4), with a mean increase of 65% versus 125% (P < 0.001). Thrombocytopenia or neutropenia occurred in 2 of 28 (7%) patients in group A versus 12 of 56 (21.4%) in group B (P = 0.1), with a mean decrease of 20% versus 45% and 25% versus 52% (P < 0.01) for neutrophils and platelets, respectively. Hyperamylasemia and symptoms of acute sialoadenitis occurred in 11 of 30 (36.6%) versus 48 of 60 (80%) (P < 0.001) and in 9 of 30 (30%) versus 35 of 60 (58.3%) (P = 0.01), respectively. 8-Epi-PGF2{alpha} was found to be elevated after 131I in 14 of 25 (56%) patients in group A versus 45 of 45 (100%) in group B (P < 0.001), with a mean increase of 60% versus 125% (P < 0.001). Conclusion: The lower radiotoxicity with rhTSH, suggested in dosimetry studies, was confirmed in the present prospective investigation, and this advantage occurred without compromising the efficacy of treatment.

Key Words: thyroid cancer • remnant ablation • rhTSH


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 CONCLUSION
 References
 
Total thyroidectomy followed by remnant ablation with 131I is the initial therapy indicated for most patients with differentiated thyroid carcinoma (1). Factors against routine postoperative ablation are the uncertainty regarding the benefit for low-risk patients (2) and the undesired effects of this procedure. Rapidly occurring (weeks) and intense (low thyroxine) hypothyroidism has been inevitable until recently for ablation with 131I, and although well tolerated, adverse effects of radioiodine, such as damage to the salivary glands (3–5), impaired gonadal function (6–9), oxidative injury (10), and even the risk of a secondary neoplasm (1), have been documented. The consequences of iatrogenic hypothyroidism (11) and adverse effects of 131I may equal or even exceed the eventual benefits of ablation, particularly in low-risk patients (1,2,12).

The use of recombinant human thyroid-stimulating hormone (rhTSH), which is known to be efficient in remnant ablation (13,14) and has already been approved for this purpose in Europe, the United States, and Brazil, solves the problem of hypothyroidism. Regarding the adverse effects of radioiodine, the lower blood and whole-body radiation obtained with rhTSH (15) indicates a probable lower risk of toxicity with this preparation without compromising its efficacy (14).

The objective of the present study was to compare the damage caused by 131I (3.7 GBq) during remnant ablation in patients prepared with rhTSH versus those who undergo levothyroxine withdrawal.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 CONCLUSION
 References
 
Patients
We studied 94 consecutive patients, seen between August 2003 and December 2006, who underwent total thyroidectomy without lymph node metastases apparent during surgery, had macroscopically complete tumor resection, and fulfilled the following inclusion criteria: age between 18 and 65 y, no associated comorbidities, a well-differentiated tumor no larger than 5 cm and with no extensive extrathyroidal invasion (16), a postoperative clinical examination and chest radiograph showing no signs of metastases, and negative for antithyroglobulin antibodies.

131I Therapy
All patients received 3.7 GBq (100 mCi) of 131I for remnant ablation without undergoing pretreatment whole-body scanning. Preparation with rhTSH was offered to all 94 patients, although none of the patients presented a contraindication for iatrogenic hypothyroidism or an apparent incapacity for endogenous thyroid-stimulating hormone elevation (17). After the patients were informed that rhTSH has still not been approved for ablation and that there is no formal indication for this preparation, 30 patients opted for levothyroxine withdrawal. In 34 of the 64 remaining patients, acquisition of rhTSH was not feasible. Thirty patients (group A) received 0.9 mg of rhTSH for 2 consecutive days followed by 131I administration on the third day. All these patients signed a consent form approved and required by the Ethics Committee of Santa Casa de Belo Horizonte because the use of rhTSH for ablation had not yet been approved in Brazil when the study was performed. The remaining 64 patients (group B) were prepared by levothyroxine withdrawal for 3–4 wk.

The subjects received instructions regarding limiting exposure to environmental iodine and using a low-iodine diet for 2 wk before 131I therapy (18). For women of child-bearing potential, a negative serum human chorionic gonadotropin pregnancy test was required. When presenting with intestinal constipation, the patients were told to drink a lot of water and were given a laxative to adequately eliminate 131I. The patients were advised to frequently chew gum, which was made freely available. Hormonal therapy was reintroduced 48 h after radioiodine administration in patients who underwent levothyroxine withdrawal.

All patients, except 2 in group B, underwent whole-body scanning 7 d after 131I administration. Five patients showed ectopic cervical uptake (lymph node) on posttherapy whole-body scanning (2 in group A and 3 in group B).

Study Protocol
The subjects were evaluated approximately 8–10 wk after thyroidectomy during levothyroxine use and also immediately before the administration of 131I to exclude those who were already showing basal changes in the parameters studied. The exclusion (clinical and laboratory) criteria are shown in Table 1. Four, 3, 21, 4, and 7 patients were excluded from the evaluation of damage to salivary glands, testes, ovaries, hematologic injury, and oxidative injury, respectively, for the reasons shown in Table 1. The patients included in the study were investigated according to the protocol summarized in Table 2.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Exclusion Criteria

 

View this table:
[in this window]
[in a new window]

  		TABLE 2 Study Protocol

 
Outcome of Ablation
Six to 12 mo after ablation, the patients were reevaluated by measurement of stimulated thyroglobulin with the same preparation as that used for ablation and neck ultrasonography. Ablation was considered to be successful when the stimulated thyroglobulin level was less than 1 ng/mL and neck ultrasonography showed no abnormalities.

Assays
Amylase was measured in serum by the purine nucleoside phosphorylase kinetic method, with a reference value of up to 104 U/L. Follicle-stimulating hormone (FSH) was determined using the IRMA FSH MAIAclone kit (BioChem Immuno Systems), with an intra- and interassay variability of 1.2%–3.5% and 2%–5.4%, respectively, and a reference value of up to 14 IU/L for men and for women in the follicular phase of the cycle (time of measurement). Leukocytes (neutrophils), platelets, and red blood cells were counted in an automated flow cytometer, and samples showing alterations in any of the series were reevaluated.

Plasma 8-epi-PGF2{alpha} was measured by a specific enzyme immunoassay (Cayman Chemical) after extraction and purification by chromatography. The mean value plus 2 SDs was 22 pg/mL for a control group consisting of 24 (16 women and 8 men) healthy nonsmoking individuals aged 18–65 y (mean, 45 y) without known disease and not using any medications. For values of approximately 5, 10, and 30 pg/mL, the intraassay variability was 3%, 3.2%, and 2.9%, respectively, and the interassay variability (interval of 2 wk) was 5%, 5.3%, and 4.5%, respectively. The detection limit calculated for 20 samples with a known zero concentration of 8-epi-PGF2{alpha} was 1.3 pg/mL. The blood samples were prepared with 2% ethylenediaminetetraacetic acid and 1 mg of acetylsalicylic acid per milliliter and were immediately centrifuged, and plasma was extracted and stored at 70°C until the time of analysis, which occurred within a maximum of 2 wk (10).

Thyroglobulin was measured by a radioimmunometric assay (ELSA-hTG; CIS Bio International), with a functional sensitivity of 1 ng/mL. Antithyroglobulin antibodies were determined by a chemiluminescent assay (Nichols Institute Diagnostics), with a detection limit of 1 IU/mL and a reference value of up to 2 IU/mL.

Imaging Methods
Ultrasonography was performed with a linear multifrequency 10-MHz transducer. All suspected lesions apparent on ultrasonography (19) were evaluated by ultrasonography-guided fine-needle aspiration biopsy.

Statistical Analysis
Results are expressed as mean ± SD or as percentage. Means were compared between groups by the Student t test or the nonparametric Mann–Whitney U test. The Fisher exact test or {chi}2 test was used to detect differences in the proportion of cases. A P value of less than 0.05 was considered to be significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 CONCLUSION
 References
 
The characteristics of the patients included in group A (rhTSH) and group B (levothyroxine withdrawal) are shown in Table 3. Uptake in the thyroid bed was no more than 2% in any patient.


View this table:
[in this window]
[in a new window]

  		TABLE 3 Characteristics of Groups A and B

 
Outcome of Ablation
The thyroglobulin level during levothyroxine therapy was no more than 1 ng/mL in any patient 6–12 mo after ablation. Ablation was successful (stimulated thyroglobulin level < 1 ng/mL and negative neck ultrasonography findings) in 27 of 30 patients of group A (90%) and in 51 of 64 of group B (80%) (not significant [NS]). Considering only patients with a thyroglobulin level greater than 1 ng/mL immediately before 131I administration, the rates were 80% in group A (12/15) and 70.6% in group B (24/34) (NS).

Adverse Effects
Only 1 patient (3.3%) reported a transient adverse effect (headache) with rhTSH during the period between the first injection and 1 wk after the second application.

For each assessment (Table 4), application of the exclusion criteria resulted in 2 groups (rhTSH vs. hypothyroidism), and these groups were also always similar in sex and age.


View this table:
[in this window]
[in a new window]

  		TABLE 4 131I-Related Adverse Effects in Groups A and B

 
We observed no difference in FSH, amylase, or blood cell count before and 24 h after the second injection of rhTSH in group A, or before and 3–4 wk after levothyroxine withdrawal in group B, with the results obtained immediately before 131I administration being defined as baseline. Serum FSH levels in men and women were similar in the 2 groups before 131I (6.5 ± 1.5 IU/L vs. 6.1 ± 1.6 IU/L [NS] and 5.2 ± 1.4 IU/L vs. 5.5 ± 1.6 IU/L [NS], respectively), as were amylase levels (56 ± 20 U/L vs. 52 ± 18 U/L [NS]). Basal platelet and neutrophil counts were normal and also similar (mean of 276,500/mm3 vs. 281,200/mm3 [NS] and 2,320/mm3 vs. 2,420/mm3 [NS], respectively), as were mean hemoglobin levels (14 g/dL in both groups). Plasma 8-epi-PGF2{alpha} levels were elevated (>22 pg/mL) before 131I in 3 of 28 (10.7%) patients in group A versus 14 of 59 (23.7%) in group B (P = 0.24). Restriction of the evaluation to patients with normal basal levels showed similar values in the 2 groups. The behavior of these markers after 131I therapy is shown in Table 4.

Follow-up
By the last assessment (June 2008), normalization of FSH had occurred in 20 of 27 patients with elevated levels of this hormone 6 mo after ablation, and platelet and neutrophil counts had also returned to normal in 10 of 12 patients with early neutropenia or thrombocytopenia after 131I administration. Six of the 7 patients who continued to show elevated FSH and the 2 patients with persistent hematologic alterations belonged to group B. Hyperamylasemia persisted in only 2 patients, also from group B, and recurrent or persistent pain or xerostomia was observed in 4 patients (1 from group A and 3 from group B). All these patients showed elevated amylase levels or acute sialoadenitis after ablation.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
CONCLUSION
 References
 
In low-risk patients, postoperative 131I has been based on the lower recurrence rate and even a lower mortality observed in the Ohio series (20), on the improvement in the specificity of thyroglobulin, and on the early detection of metastases by posttherapy whole-body scanning (20). In contrast, not all investigators have confirmed the benefit of adjuvant therapy with 131I in this group (2), with this therapy resulting in 2 relevant problems, the need for iatrogenic hypothyroidism (11) and radioiodine toxicity (1,3–10). With respect to the latter, a low activity (1.1–1.85 GBq [30–50 mCi]) is applied to minimize the adverse effects of radioiodine. Although 2 recent randomized studies confirmed the equivalent efficacy of low 131I activities both during hypothyroidism (21) and after rhTSH (22), some authors still question whether the efficacy is the same as that obtained with 3.7 GBq (23). Preparation with rhTSH is known to result in lower blood and whole-body radiation than does hypothyroidism (15,24–28). The most likely explanation is a difference in the clearance of 131I, which is lower during hypothyroidism because of a reduction in the renal glomerular filtration rate (14,15). We are unaware of any published studies that specifically evaluated radiotoxicity in patients treated with rhTSH versus hypothyroidism.

With respect to patients prepared by levothyroxine withdrawal for several weeks, our results agree well with the literature. After the administration of approximately 3,700 MBq (100 mCi), studies have reported hyperamylasemia (>200 U/L) in 40% of patients (5), a significant increase of serum amylase levels in more than 80% (4), and acute sialoadenitis in 30%–50% (5,29,30). The lack of a significant and concomitant increase in pancreatic enzymes and the presence of symptoms of sialoadenitis, but not of pancreatitis, in patients with postradiation hyperamylasemia (31,32) confirm that the increase in amylase results from salivary gland injury. Administration of 3,700 MBq (100 mCi) has also resulted in an increase in FSH in all men 6 mo after therapy (7) but in only 28% of women (8). Regarding hematologic toxicity, Lima et al. (33), using an activity of 9.25–13 GBq (250–350 mCi), observed mild or moderate thrombocytopenia and neutropenia on some occasions up to 60 d after therapy in 45% and 50% of patients, respectively. When administering an average of 7.6 GBq, Haynie and Beierwaltes (34) reported reduced values in one of the series (red blood cells, leukocytes, or platelets) in 48% of 152 patients. A radiation dose of less than 2 Gy in the blood is also known to result in only minimal and transient thrombocytopenia and leukopenia (35), as observed in the present study. Therefore, we believe that the present results have not under- or overestimated 131I toxicity.

The isoprostane 8-epi-PGF2{alpha} is generated after free radical–mediated peroxidation of arachidonic acid, and some properties render this compound a reliable indicator of oxidative stress in vivo (36): it is a specific product of lipid peroxidation, a stable compound, and present in detectable quantities in all normal biologic fluids and tissues; its formation increases dramatically in vivo after several oxidant injuries; its levels are not affected by dietary lipid content; and commercial kits are available for its measurement. 8-Epi-PGF2{alpha} is mitogenic, is a vasoconstrictor, and displays a potential proaggregation effect on human platelets, and elevated concentrations are observed in conditions such as smoking, hypercholesterolemia, diabetes, advanced age, atherosclerosis-associated diseases, and chronic lung disease (10). Wolfram et al. showed a dose-dependent increase in 8-epi-PGF2{alpha} levels in the plasma, serum, and urine of patients undergoing radioiodine therapy (10). An invariable increase in plasma 8-epi-PGF2{alpha}, 100% on average, was reported after the administration of 2.96 GBq (80 mCi) (10), in good agreement with our results.

Although not evaluated in the present study because of the obviously insufficient number of patients and follow-up time, 10 y after therapy 3 more cases of leukemia and 57 more cases of solid malignant tumors than expected would occur per 10,000 patients treated with 3,700 MBq (100 mCi) of 131I during hypothyroidism (1). Because this risk is also proportional to the radiation that reaches extrathyroidal tissues (37), preparation with rhTSH would have a favorable impact on this highly undesired effect.

The present study was not randomized, a fact that does not exclude the possibility of bias. However, the selection of patients for the use of rhTSH was not based on parameters known to influence radiotoxicity, and the groups receiving the 2 preparations were similar in sex, age, and baseline parameters. In addition, the patients originated from the same center. Thus, possible differences between groups in evaluation of the results, including the technique and the observer, are unlikely.

The radiation reaching the tissues was not directly measured. Using MIRD (38), the estimated radiation in testes and ovaries would be 85 mGy and 140 mGy, respectively, when 3,700 MBq (100 mCi) of 131I are administered during euthyroidism (as for the preparation with rhTSH). Specific studies on thyroidectomized patients during hypothyroidism suggest that the same activity would result in a testicular radiation of 86 mGy (39) to 120 mGy (40); the radiation in the ovaries would be much higher than estimated by MIRD (9), and an average radiation of 740 mGy would be obtained for the salivary glands (41). Interstudy comparison is inappropriate because of differences in the characteristics of the patients, in the preparation protocol, in the assessment techniques, and between examiners. In a randomized study involving similar groups (rhTSH vs. hypothyroidism) and a uniform assessment, Hanscheid et al. (15) reported that the radiation in blood after 3,700 MBq (100 mCi) of 131I was 0.62 Gy during hypothyroidism and 0.4 Gy for rhTSH, with this finding also suggesting a lower tissue irradiation when the latter preparation is used. Because tissue irradiation correlates with the 131I activity administered, the relationship between the latter and the increase in FSH (42), amylase (4), and 8-epi-PGF2{alpha} (10) levels and the reduction in blood cell count (37) supports the hypothesis that the magnitude of changes in these markers in fact reflects radiation reaching the respective tissues (43).

The fact that we observed no difference in FSH, amylase, or blood cell count before and after levothyroxine withdrawal, together with the finding of similar basal levels (immediately before 131I) in the 2 groups, permits us to exclude the possibility that hypothyroidism itself influenced the results. Other studies confirm that hypothyroidism results in no or only a mild increase in serum amylase (44), FSH (42), and 8-epi-PGF2{alpha} levels (45). Although the increase in these markers is not a specific radiation-induced damage, the exclusion of other causes of tissue injury and the temporal relationship permit us to conclude that the alterations observed can be attributed exclusively to radiation.

To our knowledge, only a single study has compared rhTSH and hypothyroidism in terms of radiation in blood and in whole body and also reported the efficacy of these preparations: no difference in the ablation rate (14,15). The patients included in our study were also evaluated regarding the success of ablation, and no difference was observed between preparations, a finding confirming that the lower toxicity of 131I with rhTSH occurs without compromising the efficacy of treatment.

After confirmation of the efficacy and approval of rhTSH for remnant ablation, the next step is to define the preparation of choice. The prevention of iatrogenic hypothyroidism is the main and best-known advantage of rhTSH. Short exposure to elevated thyroid-stimulating hormone, reducing the risk of tumor growth, is another potential advantage (11). The lower toxicity associated with rhTSH has been supported by dosimetry studies (15) showing lower radiation in the blood and whole body, and now by the data of the present prospective study. This advantage occurs without compromising the efficacy of treatment. These findings favor rhTSH as the preparation of choice for thyroid remnant ablation and probably the only acceptable choice in low-risk patients for whom the benefits of 131I are controversial (2) and for whom the undesired effects of this treatment need to be minimized.


   CONCLUSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 CONCLUSION
References
 
The lower radiotoxicity with rhTSH, suggested in dosimetry studies, was confirmed in the present prospective investigation, and this advantage occurred without compromising the efficacy of treatment.


   FOOTNOTES
 
COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


   References
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 CONCLUSION
 References
 

  1. Rubino C, De Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638–1644.[CrossRef][Medline]
  2. Hay ID, Thompson GB, Grant CS. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–885.[CrossRef][Medline]
  3. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001;42:738–743.[Abstract/Free Full Text]
  4. Becciolini A, Porciani S, Lanini A, Benucci A, Castagnoli A, Pupi A. Serum amylase and tissue polypeptide antigen as biochemical indicators of salivary gland injury during iodine-131 therapy. Eur J Nucl Med. 1994;21:1121–1125.[Medline]
  5. Rosario PW, Maia FF, Barroso A, Padrão EL, Rezende L, Purisch S. Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2004;48:310–314.[Medline]
  6. Wichers M, Benz E, Palmedo H, Biersack HJ, Grünwald F, Klingmüller D. Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med. 2000;27:503–507.[CrossRef][Medline]
  7. Rosario PW, Barroso AL, Rezende LL, et al. Testicular function after radioiodine therapy in patients with thyroid cancer. Thyroid. 2006;16:667–670.[CrossRef][Medline]
  8. Souza-Rosario PW, Alvarenga-Fagundes T, Villasboas Fagundes AS, et al. Ovarian function after radioiodine therapy in patients with thyroid cancer. Exp Clin Endocrinol Diabetes. 2005;113:331–333.[CrossRef][Medline]
  9. Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab. 1989;69:186–190.[Abstract/Free Full Text]
  10. Wolfram RM, Budinsky AC, Palumbo B, Palumbo R, Sinzinger H. Radioiodine therapy induces dose-dependent in vivo oxidation injury: evidence by increased isoprostane 8-epi-PGF2{alpha}. J Nucl Med. 2002;43:1254–1258.[Abstract/Free Full Text]
  11. Rosario PW, Fagundes TA, Rezende LL, Padrao EL, Borges MA, Barroso AL. Assessing hypothyroidism in the preparation of patients with thyroid cancer: cardiovascular risk, renal function, drug metabolism, persistence of elevated thyroid-stimulating hormone, and absence from work. Endocrinologist. 2006;16:25–29.[CrossRef]
  12. Rosario PW, Borges MA, Purisch S, et al. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid. 2007;17:1225–1228.[CrossRef][Medline]
  13. Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun. 2006;27:627–632.[CrossRef][Medline]
  14. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–932.[Abstract/Free Full Text]
  15. Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–654.[Abstract/Free Full Text]
  16. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer. 2002;94:2511–2516.[CrossRef][Medline]
  17. Rosario PW, Fagundes TA, Purisch S, Padrao EL, Rezende LL, Barroso AL. Recombinant TSH in ablative therapy and follow-up of patients with differentiated thyroid carcinoma. Arq Bras Endocrinol Metabol. 2005;49:350–358.[Medline]
  18. Sapienza MT, Endo IS, Campos Neto GC, Tavares MG, Marone MM. Radioiodine therapy for differentiated thyroid carcinoma: methods used to increase the radiation absorbed dose. Arq Bras Endocrinol Metabol. 2005;49:341–349.[Medline]
  19. Rosario PW, Faria S, Bicalho L, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med. 2005;24:1385–1389.[Abstract/Free Full Text]
  20. Mazzaferri EL, Kloos R. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–1463.[Free Full Text]
  21. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS ONE. 2008;3:e1885.[CrossRef]
  22. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3542–3546.[Abstract/Free Full Text]
  23. Doi SA, Woodhouse NJ, Thalib L, Onitilo A. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res. 2007;5:87–90.[Free Full Text]
  24. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1371–1377.[CrossRef][Medline]
  25. Papadimitriou D, Kottou S, Oros L, et al. Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin. Ann Nucl Med. 2006;20:63–67.[Medline]
  26. Menzel C, Kranert WT, Dobert N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I. J Nucl Med. 2003;44:1065–1068.[Abstract/Free Full Text]
  27. Vaiano A, Traino AC, Boni G, et al. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. Nucl Med Commun. 2007;28:215–223.[CrossRef][Medline]
  28. Sisson JC, Shulkin BL, Lawson S. Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retention of 131I. J Nucl Med. 2003;44:898–903.[Abstract/Free Full Text]
  29. Kita T, Yokoyama K, Higuchi T, et al. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med. 2004;18:345–349.[Medline]
  30. Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med. 2005;46:261–266.[Abstract/Free Full Text]
  31. Junglee D, Katrak A, Mohiuddin J, Blacklock H, Prentice HG, Dandona P. Salivary amylase and pancreatic enzymes in serum after total body irradiation. Clin Chem. 1986;32:609–610.[Abstract/Free Full Text]
  32. Modak S, Pandit-Taskar N, Kushner BH, et al. Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer. 2008;50:1271–1273.[CrossRef][Medline]
  33. Lima JV Jr, Campos Neto GC, Torciuncula MV, et al. Evaluation of medullary toxicity after radioiodine therapy in patients with thyroid carcinoma [abstract]. Arq Bras Endocrinol Metab. 2007;51(suppl 1):S96.
  34. Haynie TP, Beierwaltes WH. Hematologic changes observed following I-131 therapy for thyroid carcinoma. J Nucl Med. 1963;4:85–91.[Medline]
  35. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR. 1962;87:171–182.
  36. Roberts LJ, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000;28:505–513.[CrossRef][Medline]
  37. Maxon HR III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19:685–718.[Medline]
  38. Summary of current radiation dose estimates to humans from 123I, 124I, 125I, 126I, 130I, 131I, and 132I as sodium iodide. J Nucl Med. 1975;16:857–860.[Free Full Text]
  39. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf). 2002;56:755–758.[CrossRef][Medline]
  40. Ceccarelli C, Battisti P, Gasperi M, et al. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. J Nucl Med. 1999;40:1716–1721.[Abstract/Free Full Text]
  41. Kolbert KS, Pentlow KS, Pearson JR, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med. 2007;48:143–149.[Abstract/Free Full Text]
  42. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med. 1994;35:1418–1422.[Abstract/Free Full Text]
  43. Becciolini A, Porciani S, Lanini A, Balzi M, Faraoni P. Proposal for biochemical dosimeter for prolonged space flights. Phys Med. 2001;17(suppl 1):185–186.[Medline]
  44. Saha B, Maity C. Alteration of serum enzymes in primary hypothyroidism. Clin Chem Lab Med. 2002;40:609–611.[CrossRef][Medline]
  45. Kim KM, Paeng KJ, Hahm JR, Kim DR, Chung BC. Elevated urinary 8-isoprostaglandin F(2alpha) in females with Graves' hyperthyroidism. Prostaglandins Leukot Essent Fatty Acids. 2004;71:143–147.[CrossRef][Medline]
Received for publication May 30, 2008. Accepted for publication August 7, 2008.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
 JNMHome page
R. K. Grewal, S. M. Larson, C. E. Pentlow, K. S. Pentlow, M. Gonen, R. Qualey, L. Natbony, and R. M. Tuttle
Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation
J. Nucl. Med., October 1, 2009; 50(10): 1605 - 1610.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.050591v1
49/11/1776    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosário, P. W.
Right arrow Articles by Purisch, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosário, P. W.
Right arrow Articles by Purisch, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE